Understanding the gut microbiota in cancer cachexia.
Curr Opin Clin Nutr Metab Care
; 26(5): 482-489, 2023 09 01.
Article
em En
| MEDLINE
| ID: mdl-37389459
ABSTRACT
PURPOSE OF REVIEW Cachexia is a complex, multifactorial syndrome primarily characterized by weight loss, muscle wasting, anorexia, and systemic inflammation. It is prevalent in cancer patients and is associated with a poor prognosis, including lower resistance to intervention toxicity, quality of life, and survival, compared to patients without the syndrome. The gut microbiota and its metabolites have been shown to influence host metabolism and immune response. Our article reviews the current evidence suggesting a role of gut microbiota in the development and progression of cachexia, while discussing the potential mechanisms involved. We also describe promising interventions targeting gut microbiota aiming to improve outcomes related to cachexia. RECENT FINDINGS:
Dysbiosis, an imbalance in gut microbiota, has been associated with cancer cachexia through pathways involving muscle wasting, inflammation, and gut barrier dysfunction. Interventions targeting gut microbiota, such as probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, have shown promising results in managing this syndrome in animal models. However, evidence in humans is currently limited.SUMMARY:
Mechanisms linking gut microbiota and cancer cachexia need to be further explored, and additional human research is necessary to evaluate the appropriate dosages, safety, and long-term outcomes of prebiotic and probiotic use in microbiota management for cancer cachexia.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Probióticos
/
Simbióticos
/
Microbioma Gastrointestinal
/
Neoplasias
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Clin Nutr Metab Care
Assunto da revista:
CIENCIAS DA NUTRICAO
/
METABOLISMO
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Brasil